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ABSTRACT
Background: Recessive forms of osteogenesis imper-
fecta (OI) may be caused by mutations in LEPRE1,
encoding prolyl 3-hydroxylase-1 (P3H1) or in CRTAP,
encoding cartilage associated protein. These proteins
constitute together with cyclophilin B (CyPB) the prolyl 3-
hydroxylation complex that hydroxylates the Pro986
residue in both the type I and type II collagen a1-chains.
Methods: We screened LEPRE1, CRTAP and PPIB
(encoding CyPB) in a European/Middle Eastern cohort of
20 lethal/severe OI patients without a type I collagen
mutation.
Results: Four novel homozygous and compound hetero-
zygous mutations were identified in LEPRE1 in four
probands. Two probands survived the neonatal period,
including one patient who is the eldest reported patient
(177/12 years) so far with P3H1 deficiency. At birth, clinical
and radiologic features were hardly distinguishable from
those in patients with autosomal dominant (AD) severe/
lethal OI. Follow-up data reveal that the longer lived
patients develop a severe osteochondrodysplasia that
overlaps with, but has some distinctive features from, AD
OI. A new splice site mutation was identified in two of the
four probands, affecting only one of three LEPRE1 mRNA
splice forms, detected in this study. The affected splice
form encodes a 736 amino acid (AA) protein with a
‘‘KDEL’’ endoplasmic reticulum retention signal. While
western blotting and immunocytochemical analysis of
fibroblast cultures revealed absence of this P3H1 protein,
mass spectrometry and SDS-urea-PAGE data showed
severe reduction of a1(I)Pro986 3-hydroxylation and
overmodification of type I (pro)collagen chains in skin
fibroblasts of the patients.
Conclusion: These findings suggest that the 3-hydro-
xylation function of P3H1 is restricted to the 736AA splice
form.
Osteogenesis imperfecta (OI) comprises a hetero-
geneous group of conditions characterised by a
variable degree of bone fragility with susceptibility
to pathological fractures, short stature, bowing of
the long bones, wormian bones and moderate to
severe kyphoscoliosis.1 Dentinogenesis imperfecta,
blue sclerae, hearing loss and joint hyperlaxity are
variably associated features. OI is usually inher-
ited as an autosomal dominant (AD) disorder,
caused by a heterozygous mutation in either
COL1A1 (OMIM *120150) or COL1A2 (OMIM
*120160), encoding the a1 and the a2 chain of type
I (pro)collagen, respectively. Type I (pro)collagen
is the major extracellular matrix protein of both
bone and skin. It is composed of two a1(I) chains
and one a2(I) chain, each consisting of 338
uninterrupted repeats of the Gly-Xaa-Yaa motif,
in which Xaa is mostly proline (Pro) and Yaa often
hydroxyproline (Hyp). This constellation allows
the formation of a triple helix structure.2 To
facilitate folding and stability of the triple helix,
different post-translational modifications are
required in the endoplasmic reticulum (ER).3
Throughout the helical region of the collagen
chains, multiple lysine and proline residues at
the Yaa position in the Gly-Xaa-Yaa motif are
hydroxylated by lysyl hydroxylase and prolyl
4-hydroxylase, respectively. Only one single
proline residue, Pro986, at the Xaa position in
the a1 chain of type I collagen, is subjected to
3-hydroxylation. This is accomplished by the
prolyl 3-hydroxylation complex, consisting of the
enzyme prolyl 3-hydroxylase-1 (P3H1, encoded by
LEPRE1) (OMIM *610339), its helper protein
cartilage associated protein (CRTAP) (OMIM
*605497), and the prolyl cis/trans isomerase
cyclophilin B (or peptidylprolyl isomerase B)
(CyPB or PPIB) (OMIM *123841), in a 1:1:1
ratio.4
Although some recurrences in sibs of unaffected
parents have been explained by parental mosai-
cism for a mutation in one of the type I collagen
genes, the existence of recessive forms of OI has
long been suspected.5 Moreover, several new types
of OI, outside the Sillence classification into four
subtypes (OI type I-IV), have been delineated, in
some of which autosomal recessive (AR) inheri-
tance has been documented.6 Overmodification of
the proa-chains of type I collagen has been
demonstrated in some of these recessive forms,
despite the absence of mutations in either
COL1A1 or COL1A2. Recent reports of patients
with homozygous or compound heterozygous
mutations in the CRTAP or LEPRE1 gene and
severely reduced 3-hydroxylation of Pro986 in the
a1(I)-collagen chain have proved the existence of
AR inheritance in a small fraction of patients with
severe/lethal types of OI.7-10
We present the clinical and molecular findings of
four unrelated probands carrying novel mutations
in LEPRE1. The phenotype varies from perinatal
lethal to ‘‘surviving’’ phenotypes with the cur-
rently longest living patient aged 17 years
7 months.
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SUBJECTS AND METHODS
Subjects
The patients presented here belong to a larger study cohort of
20 probands with severe or lethal OI in whom no COL1A1 or
COL1A2 mutation was identified. Hence, they were screened
for LEPRE1, CRTAP and PPIB mutations. The phenotype of each
patient was clinically and radiographically compatible with OI
type II or III. Cultured skin fibroblasts were obtained from 15
probands. Nine of them showed overmodified type I collagen
chains, whereas six probands showed a normal electrophoretic
pattern for type I collagen. In the remaining five probands, only
a blood sample was available. Informed consent to perform the
biochemical and molecular studies was obtained from the
patients and/or their parents.
Mutation and haplotype analysis
Genomic DNA (gDNA) and mRNA were extracted from
fibroblast cultures using the Puregene DNA Isolation kit
(Gentra Systems, Minneapolis, Minnesota, USA) and the
RNeasy Mini Kit (Qiagen, Frankfurt, Germany), respectively.
cDNA was synthesised using the SuperScript II reverse
transcriptase kit with random hexamer primers (Invitrogen,
Carlsbad, California, USA). For gDNA screening touchdown
polymerase chain reaction (PCR) amplification of all exons of
the LEPRE1, CRTAP and PPIB genes was performed using
forward and reverse primers located in the flanking introns,
while additional exonic primers were used for cDNA screening
(primer sequences and PCR conditions available upon request).
All fragments were directly sequenced on the ABI PRISM
3730XL automated sequencer (Applied Biosystems, Foster City,
California, USA) using the BigDye terminator cycle sequencing
chemistry and compared to the wild-type sequence as
submitted to GenBank (LEPRE1: gene, NM_022356.3; protein,
NP_071751.3 – CRTAP: gene, NM_006371.4; protein, NP_
006362.1 – PPIB: gene, NM_000942.4; protein, NP_000933.1).
Nucleotides were numbered starting from the first base in the
start codon (ATG) in the cDNA reference sequence. Amino
acids were numbered from the first methionine residue.
Compound heterozygous mutations were verified to be in
trans position by sequencing the gDNA in both parents.
Control alleles from 50 non-OI individuals were sequenced to
check the causality of the encountered splice site mutation.
Microsatellite markers and SNPs in the LEPRE1 region were
taken from the Marshfield map and the HAPMAP, respectively.
Genotyping was performed on an Applied Biosystems Prism
3130XL automated sequencer (Applied Biosystems). The data
were processed using Genemapper software (Applied
Biosystems).
Cloning of PCR fragments
PCR products comprising the three LEPRE1 intron 14 splice
forms were cloned using the TOPO TA Cloning system
(Invitrogen) following the instructions of the One Shot
Chemical Transformation Protocol supplied by the manufac-
turer.
Real-time quantitative PCR (qPCR)
Skin fibroblasts were grown in 6 cm dishes to 80% con-
fluency. RNA was isolated with the RNeasy Mini Kit
(Qiagen) and cDNA synthesis was performed using the
SuperScript II reverse transcriptase kit with random hexamer
primers (Invitrogen) in a total volume of 20 ml. First, an in
silico assay evaluation for LEPRE1 qPCR primers was
performed with RTPrimerDB.11 Amplification efficiency (E)
for each primer set was determined on the basis of a sixfold
cDNA dilution series from Human qPCR Reference Total
RNA (Stratagene, Cedar Creek, Texas, USA). Only primer
pairs with E >85% were included for analysis. PCR reaction
mixtures contained Roche LightCycler SYBR Green Master
Mix, 5 mM of each forward and reverse primer and 20 ng
cDNA. Cycling conditions were as follows: 5 min at 95uC, 45
cycles at 95uC for 10 s, 60uC for 30 s and 72uC for 1 s.
Subsequently, a melting curve (60–95uC) was generated for
every amplicon to check PCR reaction specificities. qPCR
analysis was performed on the Lightcycler 480 (Roche,
Pleasanton, California, USA) device. All reactions were carried
out in duplicate and normalised to the geometric mean of two
stable reference genes, GAPDH and YWHAZ, using qBasePlus
software.12 Expression levels were determined in three
independent experiments for each cell line. Differential gene
expression was considered significant if the means differed by
at least 50% and the 95% confidence intervals of the means
did not overlap (equivalent with p,0.05).
Western blotting
Dermal fibroblasts were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum,
antibiotics, 50 mg/ml L-ascorbic acid (Sigma, St Louis, Missouri,
USA) and 230 mg/ml L-proline (Sigma). Confluent cultures were
lysed in RIPA buffer (Sigma), supplemented with a protease
inhibitor cocktail (Roche). Protein concentrations of the lysates
were measured using the BCA Protein Assay (Pierce). Samples
(30 mg protein) were subjected to 10% SDS-PAGE and then
transferred onto PVDF (polyvinylidene fluoride) membranes
(Biorad, Hercules, California, USA). The membranes were
blocked overnight at 4uC in 2% milk powder solution and
incubated with primary antibody for 90 min: mouse anti-
LEPRE1 MaxPab polyclonal antibody (Abnova, Taipei, Taiwan)
at a 1:1000 dilution and mouse anti-GAPDH monoclonal
antibody (Sigma) at a 1:6000 dilution, both in a 0.5% milk
powder solution. After washing, the membranes were incubated
with secondary antibody for 60 min: goat anti-mouse HRP-
conjugated (Pierce, Rockford, Illinois, USA), diluted 1:1000 in a
0.5% milk powder solution. The membranes were washed again
before detection of bound antibodies by enhanced chemilumi-
nescence with the SuperSignal West Dura Extended Duration
Substrate Kit (Pierce). To identify P3H1 proteoglycan core
proteins, fibroblast cell extracts and concentrated medium
fractions were treated with chondroitinase ABC (Sigma)13
before western blot analysis.
Immunocytochemistry
We grew 3.104 skin fibroblasts from patients and controls in
8 well chamber slides (Nunc) for 72 h in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf
serum, antibiotics, 50 mg/ml L-ascorbic acid (Sigma) and 230 mg/
ml L-proline (Sigma). After washing in TBS, the cells were
permeabilised and fixed in ice cold acetone (220uC) for 10 min
and blocked in 10% goat serum/TBS for 30 min. Next, the cells
were incubated with 1:100 LEPRE1 MaxPab polyclonal antibody
(H00064175-B01, Abnova), 1:500 collagen I polyclonal antibody
(Ab292-100, Abcam, Cambridge, UK) or 1:200 calnexin poly-
clonal antibody (Ab13504, Abcam) in 10% goat serum/TBS for
150 min at room temperature. The cells were then washed three
times in TBS and incubated with fluorochrome conjugated
secondary antibody in 10% goat serum/TBS for 1 h (1:1000
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Alexa fluor 488 conjugated goat anti-rabbit IgG, A11008,
Invitrogen; 1:100 Cy3 conjugated goat anti-mouse IgG,
Ab6945-100, Abcam). Finally, the slides were washed three
times in TBS, mounted in Vectashield-DAPI solution
and photographed with a Zeiss-Axio-Plan 2 epifluorescence
microscope.
Steady state collagen labelling
At confluency, fibroblasts were labelled with 14C-proline as
described previously.14 After SDS-urea-PAGE separation, the gels
were processed for fluorography, dried and visualised by
autoradiography.15
(Tandem) mass spectrometric (MS) analysis
Protein bands derived from dermal fibroblasts were excised out of
the Coomassie stained SDS-urea-PAGE gel, transferred to Biopure
Eppendorf tubes and in-gel digested with trypsin as described.16
The resulting peptide mixtures were dried in a centrifugal
vacuum concentrator and re-dissolved in 20 ml of 0.1% formic
acid in water. Half of this mixture was used for nanoLC-MS/MS
analysis using a Waters nano-Acquity high performance liquid
chromatography (HPLC) in-line coupled to a Q-TOF Premier
mass spectrometer, operated as described previously.17 The
remainder of each sample was also spectrometrically analysed
but only in MS mode (without data dependent MS/MS analysis).
Figure 1 Phenotype of autosomal recessive osteogenesis imperfecta (AR OI) due to LEPRE1 mutations. (A) Total body radiographs of neonates P1
and P4 supporting diagnosis of severe OI: lack of calvarial ossification; gracile beaded ribs with multiple fractures; platyspondyly; shortened, wide,
bowed and fractured large tubular bones. (B) Clinical pictures of P3. (I) Age 13 months: unable to lift head and sit unaided. (II) Age 10 years: wheelchair
bound patient propped into special chair and unable to sit or stand unaided. (III) Age 17 4/12 years: immobile lower limbs; relatively long hands with
hyperlax finger joints. (C) Radiographic studies in P3, showing the progression of the OCD throughout childhood and adolescence. (I) Age 3 months; (II-
V) Age 13 months; (VI-VII) 5 4/12 years; (VIII) 15 years; (IX-XII) 17 4/12 years. (D) Skeletal radiographs of P4. (I) Age 5 years; (II-III) Age 8 years. (Informed
consent was obtained from the patients for publication of this report and these photographs).
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RESULTS
Identification of LEPRE1 mutations
While no mutations were found in CRTAP and PPIB, novel
homozygous and compound heterozygous LEPRE1 mutations
were identified in four probands (supplemental fig 1A).
Proband 1 (P1) was homozygous for a frameshift mutation
(c.1365_1366delAGinsC) in exon 9, resulting in a premature
termination codon (PTC) in the same exon. Proband 2-1 (P2-1)
and his sister P2-2 were homozygous for a nonsense mutation
(c.628C.T) in exon 3. Proband 3 (P3) was found to be a
compound heterozygote for a nonsense mutation (c.1102C.T)
in exon 6 and a splice site mutation (c.2055+18G.A) in intron
14. The latter mutation was also identified in homozygous
state in proband 4 (P4). This splice site mutation was not
detected in 100 control alleles. The different ethnicity of P3 and
P4 and the different haplotype backgrounds of the mutation in
P3 and P4 argue against a founder mutation (supplemental
fig 1B).
Clinical findings
Patients P1, P2-1, P2-2 and P4 were children of consanguineous
parents of, respectively, Lebanese (P1) and Turkish (P2-1, P2-2
and P4) origin. P3 was the only child of a non-consanguineous
Belgian couple. In all of them, the diagnosis of severe OI,
reminiscent of OI type II/III, was established in utero or at birth
(x rays at birth of P1 and P4 are shown in fig 1A). P1 died at
10 months of age due to respiratory failure, and the pregnancies
of P2-1 and P2-2 were electively terminated at 20 and 18 weeks
of gestation, respectively. P3 and P4 survived and are now 17 7/12
and 8 years of age, respectively.
Clinical and radiographic features of P3 at various ages are
illustrated in figs 1B and 1C, respectively. P3 was born at
38 weeks gestation by caesarean section for breech presentation
following an uneventful pregnancy. Birth weight was 3170 g
(p50), length 43 cm (,p3) and occipitofrontal circumference
(OFC) 33 cm (p10–p50). By 3 months of age severe radiological
abnormalities were documented, including a narrow thorax,
Figure 2 Alternative splicing and quantitative polymerase chain reaction (qPCR) of LEPRE1 mRNA. (A) Schematic illustration of alternative splicing of
LEPRE1 intron 14 in a wild type (top) and the splice site mutation c.2055+18G.A allele (bottom). Enlargement of the splicing region shows the
presence of a 19 bp repeat at the exon 14/intron 14 boundary. Potential splice sites and concomitant prediction scores are marked by arrows, which
are bold in case the splice site is used in the corresponding splice form. Dotted lines point at splicing events. The splice site mutation is marked by an
asterisk in the bottom part of (A). Splice form LEPRE1a is expected not to be formed by splice site mutant alleles, while the splice site mutation is silent
in LEPRE1c. (B) Reverse transcriptase (RT) PCR of intron 14 and flanking exonic sequence with mRNA from c.2055+18G.A mutant fibroblasts (P3 and
P4) versus mRNA from controls (C), followed by cloning and sequencing of the resulting amplicons. Fibroblasts were cultured in presence and absence
of translational inhibitor cycloheximide (+/2). In control samples three different mRNA splice forms could be confirmed, whereas patient samples lack
LEPRE1a in the absence of cycloheximide. The depicted sequences are derived from P4 (LEPRE1c and LEPRE1b) and from a control (LEPRE1a). An
arrow denotes the position of the splice site mutation. (C) Relative mRNA expression of LEPRE1 determined by qPCR in fibroblasts. In patients P2-1, P2-
2 and P3 the level of LEPRE1 mRNA is significantly decreased (p,0.05) compared with the control (mean of five control fibroblast cell lines), while P4
and parents of P2-1 and P2-2 show no significant lower LEPRE1 mRNA expression compared to this control. Bars indicate the 95% confidence interval
of the mean expression.
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short irregular ribs with large calluses, pronounced platyspon-
dyly, and broad, short and fractured humeri (fig 1C.I). Nine
fractures occurred in the first 9 months of life. At 13 months
body length was hardly measurable because of painful lower
limb deformities (fig 1B.I). The fontanel was still large. The girl
had a tall forehead with frontal bossing and a narrow head, a
rather prominent chin and slightly blue sclerae. The chest was
short and narrow. At that time a skeletal survey (fig 1C.II-V)
showed poor ossification of the calvarium and wormian bones.
The humeri and the long bones in the lower limbs were much
shortened with widening and bowing of the diaphyses (fig 1C.II-
III). Extreme osteopenia and osteoporosis of the entire skeleton
was particularly pronounced in the pelvic bones that had
become barely visible. There was generalised, severe platyspon-
dyly (fig 1C.IV-V) and already a thoracic dextroconvex scoliosis
(fig 1C.V). Orthopaedic surgery at 2 8/12 years for placing of
supporting metal rods in some of the long bones did neither
alleviate the patient’s suffering nor favourably alter the natural
course. Later similar surgery was also to no avail. Radiographs at
the age of about 5 years showed, besides relentless progression
of her OI, remarkable qualitative changes in and near the distal
femoral and proximal tibial metaphyses (fig 1C.VI-VII). Besides
progressive diaphyseal widening, the osseous trabeculae had
coalesced into popcorn shaped concentric condensations leaving
cyst-like translucent open spaces in between them. The distal
femoral epiphyses were hardly visible. Trabeculation in the
diaphyses was sparse and coarse (fig1 C.VI–VII). The patient
has suffered dozens of long bone and rib fractures, but
remarkably none since the age of 15 years. Radiographs at the
age of 15 years showed funnel-type widening of both diaphyseal
ends of the tibiae, where the irregular honeycomb-like config-
uration of trabeculae had decreased considerably.
This patient, who is the longest survivor reported so far with
OI due to LEPRE1 mutations, was re-examined at age 17 4/12
years. The morbidity of her OI had still increased with nearly
continuous back pain, necessitating daily use of morphine
analogues, severe thoracic scoliosis, life threatening pulmonary
infections associated with restrictive lung disease, extreme
lumbosacral kyphosis, and nearly immobile legs. The hands
were relatively long with hyperlaxity of the finger joints
(fig 1B.III). Hearing had remained normal. The skeletal survey
confirmed the disorder’s progress. Remarkably, the humeral and
femoral ends had lost the popcorn-type dense areas and had
become even more strikingly translucent. Whereas the rhizo-
melic long bones had widened considerably, the mesomelic
diaphyses had become narrower with only widening at both
ends and a twisted ribbon-like aspect. The hands presented
rather short metacarpals with diaphyseal constriction and
widened ends, and phalanges that were similarly but more
mildly abnormal. In particular the knee joint space had been
reduced to a mere linear adjacent border between femur and
tibia (fig 1C.VIII-XII).
At age 8 years P4 was able to sit without support but unable
to stand. An older sister, who was also affected with OI, had
died at 4 1/2 years of age. P4 had a high forehead and narrow
skull, bluish sclerae, downslanting palpebral fissures, a high
arched palate, but no sign of dentinogenesis imperfecta. The
chest was asymmetric and barrel shaped with severe thoracic
kyphoscoliosis. She had an umbilical hernia. All limbs were very
short and considerably bowed and mildly twisted. The hands
were relatively long with pronounced hyperlaxity of the small
joints. The bone density score was 211 at 6 2/12 years but
improved to 26.8 after ‘‘pamidronate treatment’’ (details of
treatment not documented). Radiographs at the age of 5 years
(fig 1D.I) showed, like in P3, severely osteopenic bones. The
femoral diaphyses were bowed with widening above the blown
up fracture calluses. The proximal epiphyses, metaphyses and
femoral necks were hardly discernable and the distal metaphy-
seal ends were widened with trabecular aggregation into
similar popcorn shaped abnormalities as in P3. At age 8 years
(fig 1D.II–III) radiographs revealed extreme distal bowing of the
tibiae with narrow diaphyses. Both proximal and distal tibial
ends were widened with only partial trabecular condensation
and the visible tarsal bones were severely osteopenic. The arm
bone diaphyses were also severely bowed and narrow with
widened ends, while epiphyses and metaphyses were hardly
discernable with only a few areas of trabecular condensation.
The humerus was significantly more shortened than the
narrow, twisted ulna and radius.
Effects of LEPRE1 mutations on transcription and splicing
The effects of the identified LEPRE1 mutations on transcription,
translation and type I collagen modification were evaluated in
P2-1, P2-2, P3 and P4. For P1 no fibroblasts were available for
further studies.
The c.2055+18G.A splice site mutation, identified in P3 and
P4, is located in intron 14 of the LEPRE1 gene. LEPRE1 contains
two identical 19 bp repeats located at the exon 14/intron 14
boundary, each containing a donor splice site with a score of
0.63, according to the NNSPLICE version 0.9 splice site
prediction algorithm (http://www.fruitfly.org/seq_tools/splice.
html) (fig 2A). Use of the donor splice site in the first and
second 19 bp repeat generates two different transcripts:
LEPRE1a (Genbank: AK075418) and LEPRE1b (Genbank:
BC108311), encoding a 736AA (P3H1a) and 697AA (P3H1b)
protein, respectively. However, the SwissProt protein database
contains experimental evidence for the P3H1a protein only.18
Moreover, according to the Genbank database (AK027648), a
third transcript (LEPRE1c) with full retention of intron 14 may
also be produced that, if translated, encodes a 804AA protein
(P3H1c). The c.2055+18G.A splice site mutation increases the
score of the donor splice site in the second repeat to 0.89. This
suggests that the second repeat donor splice site will be
preferably used, resulting in the formation of LEPRE1b and
LEPRE1c transcripts only.
In order to explore the splicing pattern in patients carrying
the c.2055+18G.A mutation, we have amplified intron 14
sequence and parts of the flanking exons 14 and 15 on reverse
transcribed mRNA. By cloning and sequencing the different
bands, three different mRNA splice forms were identified in
controls, including an amplicon corresponding to the LEPRE1a
transcript, a faint band representing the LEPRE1b transcript,
and a very faint band corresponding to LEPRE1c (fig 2B). In
patient P4, homozygous for the c.2055+18G.A mutation, only
LEPRE1b and LEPRE1c transcripts were identified, prompting
the conclusion that the donor splice site in the first repeat was
completely ignored. A similar transcription pattern was
observed in the compound heterozygous patient, P3. In this
patient, the transcript from the nonsense allele is subjected to
nonsense mediated decay (NMD). LEPRE1a transcripts from
this allele can only be observed by adding cycloheximide,
an agent that is known to substantially prevent NMD. qPCR in
P2-1 and P2-2 fibroblast samples demonstrated a severe
reduction of LEPRE1 mRNA as expected from the degradation
of mutant transcripts by the NMD pathway (fig 2C). P3
showed a significantly lower LEPRE1 mRNA expression than
controls. The residual LEPRE1 transcripts are most likely derived
solely from the allele carrying the splice site mutation
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(LEPRE1b/c) and perhaps from some transcripts escaping NMD.
Patient P4, who is homozygous for the splice site mutation,
produces only LEPRE1b/c transcripts and shows hereby no
significantly lower expression than in controls. Also in hetero-
zygous carriers of nonsense LEPRE1 mutations (FP2–1/2 and
MP2–1/2), mRNA expression was not significantly different
from the control samples.
Effects of LEPRE1 mutations on translation
In silico analysis of the expected protein products of the three
observed LEPRE1 mRNA splice forms predicted the presence of
an N-terminal hydrophobic signal peptide that directs the
proteins to the secretory pathway for putative functioning in
either the plasma membrane or the extracellular matrix (fig 3A).
The presence of N-glycosylation and GAG attachment sites
suggests a function as extracellular matrix proteoglycan. In
addition, the RGD cell attachment site implies a role in cell–
matrix interaction. The C terminal ‘‘KDEL’’ ER retention signal
is present only in P3H1a, restricting it to the ER and Golgi
circuit. Western blot analysis of fibroblast lysates (fig 3B) has
confirmed the absence of intracellular P3H1 in all patients and
showed slightly reduced levels in the parents of P2-1/2,
compared to the amount detected in two control cell lines.
The protein detected in controls and parents, migrating at
¡90 kDa, most likely corresponds to P3H1a, as the P3H1a
encoding transcript is the only transcript absent in P3 and P4
(fig 2B). Although P3H1b/c are expected to be present in P3 and
P4 and in control cell lines, none of these proteins were detected
in fibroblast cell extracts, not even after treatment with
chondroitinase ABC enabling the identification of proteoglycan
core proteins (results not shown). Immunofluorescence (IF)
analysis shows that in control skin fibroblasts, P3H1 and type I
collagen co-localise exclusively in the ER, whereas none of the
P3H1 protein splice forms was detectable in any patient cell
line, consistent with the western blot results (fig 3C).
Secretion of P3H1b/c into the extracellular environment,
expected by secretory motifs in the deduced protein structure,
could not be demonstrated by western blotting of concentrated
fibroblast medium either in the patients, their parents or
controls (with or without prior treatment with chondroitinase
ABC, results not shown), although we used a polyclonal
antibody raised against a full length human P3H1 protein with
which we should be able to detect all three protein splice forms.
Effects of P3H1 deficiency on type I collagen modification
Mass spectrometry analysis of tryptic peptides of secreted a1(I)-
collagen chains revealed the severely reduced prolyl 3-hydro-
xylation at Pro986 in the a1(I) chain by the mutant P3H1
protein in patients P2-1, P3 and P4 when compared to that in a
control and parental sample (fig 4A).
As shown in fig 4B, electrophoresis of the type I collagen
chains showed only over-modified chains in P2-1, P3 and P4,
Figure 3 In silico protein structure analysis and protein expression of P3H1. (A) Schematic diagram of P3H1 splice forms. Common protein sequence
is illustrated by grey bars. Differentially striped bars show variable sequence between the three splice forms. Four glycosaminoglycan acceptor sites
(GAG), three N-glycosylation sites, an RGD motif and an N-terminal signal peptide with signal peptidase cleavage site, common to all P3H1 splice
forms, are indicated. One additional C-terminal GAG is present in P3H1a. The prolyl hydroxylase domain containing prolyl 3-hydroxylase active sites, in
addition to the C-terminal endoplasmic reticulum (ER) retention signal, KDEL, present in P3H1a only, predicts a prolyl 3-hydroxylation functioning of the
P3H1a splice form in the ER. TPR motifs are known to be involved in protein–protein interaction. (B) Western blot of fibroblast cell lysates probed with
anti-P3H1 antibody shows complete absence of P3H1 in P2-1, P2-2, P3 and P4 and slightly reduced in parents of sibs P2-1 and P2-2. The expression of
the GAPDH protein is used as a loading control. (C) Immunofluorescence analysis of P3H1 in fibroblasts. Double staining of calnexin (alexa fluor 488:
green) and P3H1 (Cy3: red) shows restriction of P3H1 to the ER. Double staining of type I collagen (alexa fluor 488: green) and P3H1 (Cy3: red) in
control fibroblasts shows co-localisation of P3H1 and type I collagen (Ab292–100) in the ER. No P3H1 can be detected in any of the patient fibroblasts.
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Figure 4 Tandem mass spectrometry and SDS-urea-PAGE of secreted type I collagen. (A) Left side: mass spectra of a1(I) collagen tryptic peptide
ions, containing hydroxylated Pro986 (doubly charged precursor at nominal m/z of 781 Th) or non-hydroxylated Pro986 (doubly charged precursor at
nominal m/z of 773 Th), shown for patients P2-1, P3 and P4, a heterozygous nonsense mutation carrier (MP3) and a control. Since both peptide forms
elute differently from RP columns, the mass spectra shown were merged over an elution window of about 1 min. Note that an additional peak at m/z of
about 777 Th is also present but the corresponding peptide was not identified by MS/MS analysis. The 3-hydroxylation at a1(I)Pro986 is low compared
to the normal level in the control and MP3. Right side: MS/MS spectra of the 781 (upper panel) and the 773 Th peptide ions, containing the a1(I)Pro986
residue (lower panel), shown for a control and P4, respectively. Following manual interpretation, the y-type of fragment ions are localising the 16 dalton
mass difference between these peptides to the C terminal five residues. Further manual interpretation leads to identification of the 781 Th ion as
collagen a1(I) 975-DGLNGLP*GPIGP+P*GPR-990 (P+ and P* denoting 3- and 4-hydroxylated proline, respectively), whereas the 773 Th ion corresponds
to collagen a1(I) 975-DGLNGLP*GPIGPP*GPR-990, thus with Pro986 in the non-hydroxylated form. For the sake of clarity, only the sequence tag that
was readable using y-type of fragment ions is shown. (B) SDS-urea-PAGE analysis of type I collagen in the fibroblast culture medium. Delay of
electrophoretic migration of type I collagen a-chains in P2-1, P3 and P4 compared to that secreted from control cell strains indicates overmodification
of all these a-chains.
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contrary to what is observed in severe AD OI, where usually
both normal and aberrantly migrating type I collagen chains are
seen.
DISCUSSION
In four unrelated probands with severe OI without COL1A1 or
COL1A2 mutation, four novel mutations in the LEPRE1 gene
were detected. The frameshift and nonsense mutations in P1
and P2–1/2 respectively and the splice site mutation in P4 are
homozygous and associated with parental consanguinity. P3,
the longest survivor among all OI patients with LEPRE1
mutations reported so far, is compound heterozygous for the
same splice site mutation as in P4 and a novel nonsense
mutation.7 10
Our observations confirm the conclusion by others10 that, in
the perinatal period, it is very difficult to distinguish radio-
graphically severe OI due to LEPRE1 mutations from severe OI
caused by COL1A1 or COL1A2 mutations. A similar conclusion
has recently been drawn regarding the CRTAP mutations.10
However, with increasing age some distinctive clinical and
radiologic features become apparent. Long term survivors with
OI due to LEPRE1 mutations present a particularly severe
phenotype, which significantly impairs quality of life, as
illustrated in P3, who has required daily use of morphine
analogues for several years. Clinically, extreme short stature and
shortening of the four extremities, with rhizomelia of both
upper and lower limbs, is striking in both P3 and P4. In both
patients the forehead with frontal bossing is remarkably tall and
narrow. The OFC in P3 is only relatively macrocephalic.
Osteoporosis is particularly severe, with DEXA Z-scores that
are generally lower than those seen in AD OI.7 In the
radiographic follow-up in P3, three consecutive stages can be
discerned. In infancy and early childhood, lack of long bone and
vertebral remodelling and growth results mainly in rhizomelic
long bones, diaphyseal widening and bowing as well as
widening and deformation of all epi- and metaphyses. The
second stage is apparent from mid-childhood. Continuing long
bone deformation is associated with peculiar agglomeration of
the bony trabeculae, especially prominent in the wide meta-
physeal ends in the knees. It results in round popcorn shaped
dense and cyst-like translucent areas organised in a honeycomb-
like pattern. The first and second radiographic stages were
observed also in the 8-year-old P4. Beyond the age of 15 years,
the third stage is noticeable in P3 and is characterised by a
complete disappearance of the honeycomb-type trabecular
agglomeration, extreme osteoporosis and additional widening
of the rhizomelic diaphyses, but progressive narrowing and
bowing of the mesomelic diaphyses. The knee joint spaces have
been reduced to a mere line between the femora and tibiae. We
have not observed similar features in several long term surviving
OI type III patients with documented COL1A1 or COL1A2
mutation.
On the one hand, the lack of prolyl-3 hydroxylation most
probably has its severe phenotypic effects because of abnormal
posttranslational modification of type I collagen molecules,
which were also shown to have a moderately slower but
increased secretion than in control cells.7 On the other hand
P3H1 deficiency also affects the structural integrity and
maintenance of type II collagen in human cartilage. This
combined adverse effect had already been documented in Crtap
-/- mice, which show decreased prolyl 3-hydroxylation in
cartilage, as well as abnormalities in the growth columns of
proliferating chondrocytes of the growth plate.8 Together,
these findings suggest that recessive OI due to defects in the
prolyl 3-hydoxylation complex is in fact an osteochondrodys-
plasia (OCD), characterised by both defects in cartilage and
bone. The contribution to the disease phenotype of deficient
prolyl 3-hydroxylation of type IV and V collagen, which contain
multiple prolyl 3-hydroxylation sites, remains unclear, although
overmodification of type V collagen, which is present in
association with type I collagen in skin and bone, has been
shown in patients with P3H1 deficiency.7
This report brings the number of already characterised
mutations in LEPRE1 to 17, 16 of which would be expected to
affect all three LEPRE1 mRNA splice forms detected in this
study, and most of which would be expected to result in
severely decreased levels of total LEPRE1 mRNA.710 It is of
interest that the splice site mutation identified in P3 and P4
affects only one of the three LEPRE1 mRNA splice forms
(LEPRE1a). Western blotting and IF analysis of fibroblast
cultures both revealed the absence of the corresponding protein
splice form P3H1a (736AA) in P2-1, P3 and P4. Moreover, mass
spectrometry showed severe reduction of a1(I)Pro986 3-hydro-
xylation in these probands, resulting in overmodification of
type I (pro)collagen chains in skin fibroblasts on SDS-urea-
PAGE. This overmodification results from a longer exposure of
the collagen chains to lysyl and prolyl 4-hydroxylation due to
delayed collagen type I triple helix formation in P3H1 deficient
cells.7 The fact that the reduction of prolyl 3-hydroxylation in
P3 and P4, both carrying the splice site mutation, was
comparable to that in P2-1, homozygous for a nonsense
mutation, supports the notion that a1(I)-Pro986 hydroxylation
is restricted to P3H1a. Some residual 3-hydroxylation activity
was detectable in the patients, despite the absence of detectable
P3H1 protein on western blot and IF analysis. This could
indicate compensation for P3H1 loss-of-function—for example,
by other members of the P3H family members, such as P3H2
or P3H3.19 Tiainen et al20 showed that recombinant P3H2
hydroxylates a synthetic peptide corresponding to the single
prolyl 3-hydroxylation site in the a1(I) collagen chain. P3H1a
is the only protein splice form that contains the ‘‘KDEL’’
ER retention signal. The retention of P3H1a in the ER, where
it co-localises with type I collagen and exerts its prolyl
3-hydroxylation function, was demonstrated by means of IF
analysis. Hence, only P3H1a would catalyse the prolyl
3-hydroxylation, known to occur in the ER, and therefore
P3H1a probably represents the true prolyl 3-hydroxylase-1.
The non-redundant function of P3H1a and P3H1b/c suggests
distinct roles of the latter splice forms. The in silico protein
structure analysis predicts that the splice forms P3H1b/c are
directed towards the secretory pathway with a putative
function in the extracellular matrix. In addition, the presence
of N-glycosylation sites, GAG attachment sites and an RGD cell
attachment site supports the idea of their role as extracellular
matrix cell attached proteoglycan. Wassenhove-McCarthy et al21
isolated P3H1 as the chondroitin sulfate proteoglycan, leprecan,
from a rat L-2 cell line and localised the proteoglycan to
basement membranes. Irrespective of a role as matrix proteo-
glycan for P3H1b/c, we have been unable to detect any
corresponding protein in the medium and cellular fractions of
fibroblast cell cultures, using a polyclonal antibody raised
against the full length human P3H1 protein. This paradox
may be explained by the possibly low abundance of these
proteins in fibroblast cultures, in which the medium fraction
differs substantially from the natural extracellular environment
of skin. Preferably, bone or skin extracellular matrix extracts
should be used to study proteoglycans secreted into the
extracellular matrix. On the other hand, the alternative splicing
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may have an on-off switch role, regulating the amount of
biologically active protein (P3H1a) with only poor or no
translation of splice forms P3H1b/c, a mechanism which has
been shown earlier for other genes.22 It is of interest that so far
no LEPRE1b/c transcripts have been detected in closely related
species such as Mus musculus or Rattus norvegicus and conserva-
tion of intron 14 is also low between the latter species and Homo
sapiens.
Electrophoresis of type I (pro)collagen chains in fibroblasts
can be helpful in the detection of LEPRE1 mutations, since in
this instance only over-modified type I collagen chains are
detected, in contrast to what is observed in severe AD OI,
where both normal and aberrantly migrating type I collagen
chains are usually seen. The latter distinction, however, is less
clear for collagen studies performed in fetal cells, in which
collagen chains show a variable delay in electrophoretic
mobility. In our experience, COL1A1/COL1A2 mutations are
identified in ,93% of OI patients with a documented
abnormal electrophoretic pattern for type I collagen. So far,
the proportion of LEPRE1 mutations in this cohort is ,3%.
Hence, mutations in LEPRE1/CRTAP account for only a small
proportion of patients with severe/lethal OI. Other, yet to be
identified, genes may be involved in the pathogenesis of OI.
Candidates may have a role either in post-translational
modification of type I collagen and/or intracellular trafficking
of collagen components.
In conclusion, we present four novel LEPRE1 mutations in
four unrelated probands with a severe congenital OCD with
important growth deficiency, many fractures and extreme
skeletal undermineralisation that, at birth, cannot be distin-
guished from OI in patients with COL1A1/COL1A2 mutations.
Clinical follow-up of the longest survivor of AR OI due to
LEPRE1 mutations provides evidence for the evolution towards
a particularly severe OCD with distinct clinical and radiographic
features. Obviously the prospective study of the natural course
in long term surviving patients with severe OI with known
causal mutations will establish more firmly whether or not
specific OI phenotypes may be assigned to some or all of the
different genotypes. The finding of the newly identified splice
site mutation that specifically affects the P3H1 splice form
responsible for a1(I)Pro986 3-hydroxylation, kindles interest in
the role and function of the other splice forms of P3H1 (LEPRE1
transcripts) that cannot rescue this hydroxylation activity.
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